Manee Raksakietisak
Bangkok, 10700, Thailand
NCT Number: NCT01643135
Tranexamic acid has benn widely used to reduce perioperative bleeding in several operations such as cardiac surgery, liver transplant and joint arthroplasty with good results. Few studies in laminectomy had conflicting results and varying in doses. The objective is to compare perioperative bleeding in major laminectomy between patients receive doubles doses of tranexamic acids (15 mg/kg and 15 mg/kg) with who receive pacebo (0.9% NaCl).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
Bangkok, 10700, Thailand
78 patients undergoing major laminectomy (with instrumentation or equal or more than 3 levels laminectomy) will be enrolled. We exclude patients who age over 65, anemia, allergy to tranexamic acid, history of deep vein thormbosis (DVT), ischemic heart disease (IHD), pulmonary embolism (PE), strokes, liver disease, chronic kidney disease with creatinine >2.0 mg/dl, and coagulopathy. After randomization, before induction and 3 hour after the first dose, patients will receive study drug or placebo intravenously. The standard anesthesia and monitoring will be tha same for all of the patients. Perioperative mild hypotensive technique will be used with the mean arterial pressure more than 60 mmHg and nearly the end, the blood pressure will be back to normal for the bleeding check. Hematocrit will be monitored at the begining and every two hours. Blood will be given if the hematocrit is below 30%. The perioperative fluid will be managed by anesthesiologist who will not know the patients' groups. The next morning, the hematocrit and blood creatinine will be checked and if the hematocrit is lower than 30%, blood will be given. Perioperative blood loss, total fluid and blood transfusion within 24 hours will be recorded. If there are any suspected symptoms and signs of DVT, angina, CHF, PE, strokes or other complications, the necessory investigations will be done for the definite dignosis and the appropriate treatment will be started immediately.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
Other names: transamine (Daiichi-Sankyo, Japan)
0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
Other names: NSS
Time frame: 24 hours
Intraoperative and postoperative blood loss will be measured by from swab, suction and vaccum drainage
Time frame: 24 hours
When the blood loss more than acceptable and the hematocrit below 30%, the packed red cell will be given.
Mahidol University
Other
Reduction Perioperative Bleeding in Laminectomy With Instrumentation or More Than or Equal to 3 Levels Laminectomy: The Comparison Between Placebo, and Double Doses of Tranexamic Acid (15 mg/kg and 15 mg/kg)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737366
Anxiety, Anxiety Disorders
Sakarya, Turkey (Türkiye)
View Trial DetailsNCT07638930
Bleeding, Hemorrhage
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT07640399
Bleeding, Gingival Diseases
Mississauga, Ontario, Canada
View Trial DetailsNCT07627789
Bleeding, Hemorrhage
Warsaw, Mazovian, Poland
View Trial Details